Didier Raoult takes hydroxychloroquine battle to court
Didier Raoult, director of the IHU, the Institute of Infectious Diseases in Marseille and one of the first to champion the use of hydroxychloroquine (HCQ) for COVID-19 treatment, has filed a complaint against the National Agency for the Safety of Medicines and Health Products (ANSM). Raoult’s legal representative, Fabrice di Vizio, states that the French health agency is “endangering the lives of others” by preventing doctors from prescribing HCQ for COVID-19 cases. Di Vizio adds, “it is well known that remdesevir is a dangerous and ineffective product. The criminal judge will intervene to find out if there is any contact between members of the ANSM and people from the Gilead laboratory”. [Gilead is the maker of Remdesevir. To learn more, read WHO study shows remdesivir offers no benefit to COVID-19 patients].
ANSM says that its decision was justified by the numerous studies showing that the data supporting the efficacy of HCQ is “very heterogenous… it does not allow us to predict a benefit of hydroxychloroquine, alone or in combination, for the treatment or prevention of COVID-19 disease”. this being questioned in court
The original article attached below is in French. You may use DeepL Translate to translate the document to English.
Editor’s Note: There is a huge body of evidence showing the efficacy of hydroxychloroquine [see Hydroxychloroquine can dramatically ease the COVID-19 crisis]. Moreover, the “anecdotal” cases of COVID-19 recovery using HCQ treatment are numerous. Meanwhile, studies showing the inefficacy of HCQ are either faulty, or are outright fraud [see Scientific fraud at top medical journals affect world COVID-19 policy].
Un recours en justice contre le refus d’autoriser massivement l’hydroxychloroquine
L’avocat Fabrice di Vizio dépose un recours au Conseil d’Etat et une plainte au pénal après le refus de l’Agence du médicament d’autoriser p
Click the button below if you wish to read the article offline.